HK1209122A1 - 多晶型物 - Google Patents

多晶型物

Info

Publication number
HK1209122A1
HK1209122A1 HK15109889.8A HK15109889A HK1209122A1 HK 1209122 A1 HK1209122 A1 HK 1209122A1 HK 15109889 A HK15109889 A HK 15109889A HK 1209122 A1 HK1209122 A1 HK 1209122A1
Authority
HK
Hong Kong
Prior art keywords
polymorph forms
polymorph
forms
Prior art date
Application number
HK15109889.8A
Other languages
English (en)
Inventor
Toyoharu Numata
Hideyuki Aoyama
Kaori Muraji
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of HK1209122A1 publication Critical patent/HK1209122A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK15109889.8A 2012-11-21 2015-10-09 多晶型物 HK1209122A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729174P 2012-11-21 2012-11-21
PCT/JP2013/006853 WO2014080633A1 (en) 2012-11-21 2013-11-21 Polymorph forms

Publications (1)

Publication Number Publication Date
HK1209122A1 true HK1209122A1 (zh) 2016-03-24

Family

ID=50775828

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15109195.7A HK1208457A1 (zh) 2012-11-21 2015-09-18 多晶型物
HK15109889.8A HK1209122A1 (zh) 2012-11-21 2015-10-09 多晶型物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15109195.7A HK1208457A1 (zh) 2012-11-21 2015-09-18 多晶型物

Country Status (13)

Country Link
US (1) US10179779B2 (zh)
EP (1) EP2922849B1 (zh)
JP (1) JP5903681B2 (zh)
KR (1) KR102191822B1 (zh)
CN (2) CN104837836B (zh)
BR (1) BR112015011392A2 (zh)
CA (1) CA2890861C (zh)
ES (1) ES2637539T3 (zh)
HK (2) HK1208457A1 (zh)
MX (1) MX353994B (zh)
RU (1) RU2659036C2 (zh)
TW (1) TWI610929B (zh)
WO (1) WO2014080633A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355697B (es) * 2010-04-12 2018-04-27 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ES2188584T3 (es) 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US8816090B2 (en) * 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
IN2012DN06631A (zh) * 2010-02-16 2015-10-23 Pfizer
US8953631B2 (en) 2010-06-30 2015-02-10 Intel Corporation Interruption, at least in part, of frame transmission
BR112013029319A2 (pt) * 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4

Also Published As

Publication number Publication date
MX353994B (es) 2018-02-07
CA2890861C (en) 2021-03-30
TW201439088A (zh) 2014-10-16
MX2015006270A (es) 2015-08-07
HK1208457A1 (zh) 2016-03-04
KR20150085515A (ko) 2015-07-23
CN104837836B (zh) 2018-07-03
US10179779B2 (en) 2019-01-15
KR102191822B1 (ko) 2020-12-16
EP2922849A1 (en) 2015-09-30
RU2659036C2 (ru) 2018-06-27
CN104837836A (zh) 2015-08-12
US20150322055A1 (en) 2015-11-12
BR112015011392A2 (pt) 2017-07-11
CN108658964B (zh) 2021-07-02
JP5903681B2 (ja) 2016-04-13
CN108658964A (zh) 2018-10-16
TWI610929B (zh) 2018-01-11
RU2015123687A (ru) 2017-01-10
WO2014080633A1 (en) 2014-05-30
EP2922849B1 (en) 2017-07-12
CA2890861A1 (en) 2014-05-30
EP2922849A4 (en) 2016-03-30
JP2015536903A (ja) 2015-12-24
ES2637539T3 (es) 2017-10-13

Similar Documents

Publication Publication Date Title
HRP20181889T1 (hr) Spojevi tetrahidropirazolopirimidina
HK1245780B (zh) 咪唑並吡咯烷酮化合物
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
HK1206726A1 (zh) 咪唑並三嗪酮化合物
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1211283A1 (zh) 化合物
GB201209096D0 (en) Compounds
GB201202393D0 (en) Polymorphs
GB201219820D0 (en) Compounds
HK1206356A1 (zh) -取代的氰基吡唑化合物
GB201217310D0 (en) Compounds
HK1209122A1 (zh) 多晶型物
HK1210179A1 (zh) 多晶型物
GB201203914D0 (en) Polymorphic form
GB201203906D0 (en) Polymorphic Form
GB201203900D0 (en) Polymorphic form
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds